Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).
On May 27 the company was downgraded from “Outperform” to “Market Perform” by BMO Capital. On May 26, 2016 the stock rating was changed to a “Market Perform” by Cowen & Company down from the previous “” rating.
Equity analyst BMO Capital added IONS to its research portfolio with an initial rating of “Outperform”. On March 2 JP Morgan maintained a stock rating of “Neutral” and moved down the price target from $68.00 to $64.00.
February 24 investment analysts at Barclays left the stock rating at “Equalweight” and lowered the price expectation to $42.00 from $65.00.
The company is trading down by -1.42 percent from yesterday’s close. Shares are trading at $36.20 a tad above $32.54, the 50 day moving average and just above the 200 day moving average of $32.40. The 50 day moving average was up $3.66 whereas the 200 day moving average was up $3.80 or +11.71%.
In the last earnings report the EPS was $-1.88 and is projected to be $-1.07 for the current year with 120,919,000 shares outstanding. Next quarter’s EPS is forecasted to be $-0.13 with next year’s EPS anticipated to be $-1.01.
Investors are more bullish on shares of the company of late if you look at the change in short interest. The stock recorded a fall in short interest of -0.09% as of the latest report on September 15, 2016. Short shares fell 1,328,419 over that period. With short interest at 12,673,799 and short average daily volume at 1,589,909, days to cover is 0.0 and the percentage of shorted shares was 0.10% on September 15.